VVOSHealthcare · Medical DevicesVVOS Stock Forecast: Vivos Therapeutics, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Vivos Therapeutics, Inc. hold a median 12-month price target of $2.5 — +494.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
VVOS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Vivos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Vivos Therapeutics, Inc. — and when they’d sell — is the membership.
VVOS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VVOS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +494.4% from it.
Of the 15 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 June 2026 | Ascendiant Capital | Maintains | Buy | $3.00 → $3.10 |
| 22 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 17 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 17 Nov 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 9 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 15 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 20 Nov 2024 | Ascendiant Capital | Reiterates | Buy | — |
| 19 Nov 2024 | Alliance Global Partners | Maintains | Buy | — |
| 20 Aug 2024 | Ascendiant Capital | Maintains | Buy | — |
| 17 Jan 2023 | Ascendiant Capital | Initiates | Buy | $2.50 |
| 13 Aug 2021 | Roth Capital | Maintains | Buy | $11 → $10 |
| 18 May 2021 | Roth Capital | Maintains | Buy | $12 → $11 |
| 11 Jan 2021 | Craig-Hallum | Initiates | Buy | — |
| 5 Jan 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VVOS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Vivos Therapeutics, Inc. (VVOS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- 0.3×
- Price / book
- 1.3×
- EV / EBITDA
- −0.7×
Cheaper than 77% of US stocks
Cheaper than 90% of US stocks
Cheaper than 61% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- 70.5%
- Earnings growth (YoY)
- 70.5%
- Gross margin
- 59.5%
- Operating margin
- −128.7%
- Net margin
- −127.7%
Higher than 91% of US stocks
Higher than 82% of US stocks
Higher than 74% of US stocks
Higher than 13% of US stocks
Higher than 4% of US stocks
- Return on equity
- −1599.8%
- Return on assets
- −77.7%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
VVOS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VVOS appears on the weeks it earns a place.
Frequently asked questions about VVOS stock
What is the VVOS stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Vivos Therapeutics, Inc. have a median 12-month price target of $2.5, with estimates ranging from $0.75 to $3.1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VVOS stock a buy right now?
Of the 3 analysts covering Vivos Therapeutics, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivos Therapeutics, Inc. 12 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VVOS?
As at 1 Aug 2026, Vivos Therapeutics, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
Will VVOS stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +494.4% from the last close, and Ticker Nerd's factor model ranks Vivos Therapeutics, Inc. 12 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VVOS stock forecast for 2030?
No analyst covering Vivos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VVOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.75 to $3.1 over the next 12 months.
How has VVOS stock performed over the past year?
Vivos Therapeutics, Inc. returned -91.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Vivos Therapeutics, Inc. do?
Vivos Therapeutics, Inc. is a medical technology company that concentrates on addressing sleep apnea through innovative treatment solutions.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. is a medical technology company that concentrates on addressing sleep apnea through innovative treatment solutions. Primarily known for its proprietary systems and devices, the company offers a non-surgical approach designed to improve airway function and alleviate symptoms for patients suffering from obstructive sleep apnea (OSA), a common and often undiagnosed condition linked to various health issues. Operating at the intersection of medical devices and dental care, Vivos provides its solutions primarily to healthcare professionals, enabling them with tools and training necessary to effectively manage and treat sleep disorders. This focus on a non-invasive methodology has positioned Vivos as a notable player in the sleep disorder treatment market. Its approach not only aims to provide relief for individuals but also reduces dependency on traditional continuous positive airway pressure (CPAP) machines. Vivos Therapeutics plays a significant role in enhancing patient care within the healthcare sector by bridging the gap between dentistry and medicine, helping to raise awareness and offer alternative treatments for sleep-related breathing disorders.
CEO Mr. R. Kirk Huntsman · 270 employees · United States · https://www.vivos.com